DLL3 x B7H3 bispecific ADC (GeneQuantum Healthcare)

DLL3/B7H3双特异性ADC (启德医药)

Report date: 2026/05/09 20:00:18

Base Information

Drug NameDLL3 x B7H3 bispecific ADC (GeneQuantum Healthcare)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Delta-like protein 3Anti-CD276DNA topoisomerase I inhibitors
TargetsDelta-like protein 3CD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGeneQuantum Healthcare (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGeneQuantum Healthcare (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A